• Professional Development
  • Medicine & Nursing
  • Arts & Crafts
  • Health & Wellbeing
  • Personal Development

1580 Educators providing Courses

Ptrc Education And Research Services

ptrc education and research services

London

We specialise in training and staging events on all matters relating to transport and travel planning for consultants, local authorities, government bodies and universities in the UK and overseas. We have developed a range of technical courses that are likely to appeal to newer engineers, planners and technicians, including those who have been recruited from a non-technical background. We offer a variety of training and education formats, from evening lecture series such as the “Principles of Traffic and Transport”, to one and two day public courses like “Planning Public Transport Services". News We found Britain’s greenest city centre – and its least green Jake M Robinson, Paul Brindley 25 November 2022/Number of views (142) Why UK railways can’t deal with heatwaves – and what might help Kangkang Tang, Brunel University London 19 August 2022/Number of views (492) Good To Go? Decarbonising Travel After the Pandemic David Metz We have built our modern economy and lifestyles on the energy of fossil fuels. We know we must cease their use if dangerous climate change is to be avoided. Transport is the largest contributor to... 22 July 2022/Number of views (695) RSS Transport Practitioners' Meeting Mark your calendars! #2023TPM will take place 28 - 29 June 2023! TPM navy turqouise 2020 Advancing skills knowledge with PTRC Whether you are new to the transport industry, are looking to refresh your knowledge on transport principles, or if you have taken on a new responsibility or are working in a ‘niche area’ and wish to broaden your knowledge, PTRC’s 20 week evening lecture series offers a cost-effective and time-inexpensive training course that will benefit both the participating The next session starts soon! More information here... Upcoming Training The Principles of Traffic and Transport - The 20 Week Evening Lecture Series Our most popular lecture series provides an introduction to the key components of transport planning and traffic engineering. Whether you are new to the transport industry, are looking to refresh your knowledge on transport principles, or if you have taken on a new responsibility or are working in a ‘niche area’ and wish to broaden your knowledge, PTRC’s evening lecture series offers a cost-effective and time-inexpensive training course that will benefit both the participating employees and their employers. The programme has been designed to complement both the TPS Professional Development Scheme and the CIHT/TPS Transport Planning Professional (TPP) qualification enabling participants to gain knowledge across all the mandatory units. Upcoming Dates: 20 September 2022 - UK Online 28 September 2022 - Ireland Online 28 September 2022 - Toronto Online 06 October 2022 - London in-person

Pcsk9 Education And Research Forum

pcsk9 education and research forum

Alcester

Reducing low density lipoprotein (LDL) cholesterol is the priority in managing patients with severe dyslipidaemia (cholesterol abnormality) and at high risk of cardiovascular (CV) death and disability. Yet even when treated with potent statins, many patients fail to achieve LDL-cholesterol targets and therefore their risk of accelerated atherosclerosis and CV death remains high. This problem is particularly critical in patients with familial hypercholesterolaemia (FH) (the most commonly occurring genetic condition in the world). People with FH typically have very high LDL cholesterol levels on treatment, and consequently, are at very high risk of premature and sudden CV death, myocardial infarction and stroke. Additionally, some patients are unable to tolerate statins – particularly at higher doses – and, therefore, do not achieve LDL-cholesterol goals. What is the importance of PCSK9? Discovered in 2003,1 PCSK9 is a protein made by the liver which increases the removal of LDL receptors from the surface of liver cells. These LDL receptors are critically important in removal of serum LDL-cholesterol from the circulation. People with so-called ‘gain of function’ PCSK9 mutations over-express PCSK9, and therefore have very high plasma levels of LDL cholesterol and are at very risk of atherosclerosis and CV mortality and morbidity.2 In contrast, people with so-called ‘loss of function’ PCSK9 mutations, have very LDL cholesterol levels and reduced risk for heart disease.3 What is PCSK9 inhibition? Different approaches to lowering PCSK9 are now licensed. These include fully human monoclonal antibodies (alirocumab, evolocumab) and a small-interfering RNA therapy (inclisiran). Trials show that these PCSK9 inhibitors reduce LDL cholesterol levels by about 50-60 percent - a significantly greater effect than that achieved with currently available therapies – either when given alone or in combination. These LDL cholesterol lowering effects have been consistently across a broad group of patients, including those with familial hypercholesterolaemia in clinical trials.4 Which clinical settings will benefit from the availability of PCSK9 inhibitors? These treatments offer the potential to reduce cardiovascular risk in patients whose clinical needs cannot be satisfied by current therapy. These include: Patients with familial hypercholesterolaemia – an inherited disorder of lipid metabolism with a very high risk of early CV death or morbidity, if not diagnosed or treated early Patients who cannot tolerate statins, who therefore remain at high risk of CV events such as heart attacks and strokes Patients with established heart disease who have not achieved LDL-cholesterol goals despite current therapies